ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, March 9, 2026 at 5:30 a.m. PT / 8:30 a.m.

GlobeNewsWire • Feb 23, 2026

Got $300? 2 Biotech Stocks to Buy and Hold Forever

Krystal Biotech pioneered the first topical gene therapy. ARS Pharmaceuticals introduced the first needle-free therapy to treat anaphylaxis.

The Motley Fool • Feb 16, 2026

ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock

SPRY's main product is Neffy, which is a needle-free epinephrine spray. Its sales are ramping quickly, and Q3 2025 sales hit $31.3 million. My core thesis is that Neffy's more convenient delivery mechanism will resonate with patients far better than injections. Also, a convenient nasal spray is a much simpler administration method that should reduce user error and unlock diagnosed-but-untreated anaphylaxis demographics.

Seeking Alpha • Feb 14, 2026

ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

-Five poster presentations highlight clinical advancement of  neffy , real-world usability and advantages of needle-free epinephrine delivery -Longer shelf life of nasal epinephrine compared with epinephrine auto-injectors translates into a more affordable, value-based price -When factoring in patients' dislike of needle-based administration, the value of a nasal option increased by more than 25% SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that five poster presentations, one healthcare professional (HCP) case report, plus two late breakers from partners at ALK-Abelló A/S (ALK) centered on  neffy , will be featured at the 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting, February 27 to March 2, 2026 in Philadelphia, Pennsylvania. The posters highlight health-economic analyses, patient preference research, usability and pharmacokinetic comparisons evaluating neffy relative to injectable epinephrine products.

GlobeNewsWire • Feb 10, 2026

EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to

EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma's partner, ALK-Abelló A/S, who owns the rights to market  EURneffy  in the EU, will distribute following expected authorization by the European Commission SAN DIEGO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending expanding the marketing authorization for EUR neffy ® to include a 1 mg nasal adrenaline spray. EUR neffy 1 mg is for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens, as well as idiopathic or exercise-induced anaphylaxis, in children who weigh ≥15 kg and

GlobeNewsWire • Feb 2, 2026

California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use

California joins 23 other states eligible to receive free neffy ® (epinephrine nasal spray) at schools SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced today that California, the state where ARS Pharma is headquartered, is now eligible for its neffy inSchools program. Type 1 allergic reactions, including anaphylaxis, can happen quickly and be caused by foods, insects, medication, exercise, or other unknown causes and can only be treated with epinephrine.

GlobeNewsWire • Jan 21, 2026

Bad News For Competitor Turns Into Big Win For ARS Pharma Stock

ARS Pharmaceuticals Inc. (NASDAQ: SPRY) stock rose Friday in reaction to a negative update for its rival Aquestive Therapeutics Inc. (NASDAQ: AQST).

Benzinga • Jan 9, 2026

neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)

neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children ( > 30 kg) living with severe allergic reactions Pediatrix Therapeutics, which has a license from ARS Pharma to market  neffy  in China under the trade name 优敏速 ® , expects availability in the spring of 2026 SAN DIEGO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced that the National Medical Products Administration (NMPA) in China has granted approval for  neffy 2 mg (epinephrine nasal spray) for the emergency treatment of Type 1 allergic reactions (anaphylaxis) in adults and children who weigh 30 kg or more. In China, the trade name is 优敏速 ® meaning “Excellent Allergy (treatment) Fast”.

GlobeNewsWire • Dec 29, 2025

ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

SAN DIEGO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced its participation at the Piper Sandler 37th Annual Healthcare Conference, December 2-4, 2025, in New York.

GlobeNewsWire • Nov 26, 2025

ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating

ARS Pharmaceuticals, Inc. delivered strong Q3 Neffy sales, doubling sequentially, but remains unprofitable with high SG&A expenses and no 2026 guidance. SPRY faces competitive threats from generics and upcoming alternatives, but patent litigation could delay generic Neffy entry until 2039. Neffy's needle-free, lower-cost profile is driving adoption, with growing prescriber base and international launches, but long-term profitability remains uncertain.

Seeking Alpha • Nov 10, 2025